Table 2 Comparison of Clinicopathological Variables between ypTNM group and pTNM (n = 756) after Propensity Score-matching Using the Greedy Nearest Neighbor Algorithm without Replacement (Caliper Width 0.2 × Standard Deviation of Logit Propensity Score])
Characteristics | ypTNM (N = 378) | pTNM (N = 378) | P value* |
|---|---|---|---|
Age (μ ± sd) | 59.2 ± 10.5 | 59.3 ± 10.7 | 0.82 |
Female | 97 (25.66%) | 88 (23.28%) | 0.45 |
Family history of cancer (yes) | 74 (19.58%) | 71 (18.78%) | 0.78 |
BMI (μ ± sd, kg/m2) | 23.5 ± 3.3 | 23.5 ± 3.6 | 0.96 |
ECOG | 0.81 | ||
0 | 249 (65.87%) | 257 (67.99%) | |
1 | 111 (29.37%) | 105 (27.78%) | |
2 | 18 (4.76%) | 16 (4.23%) | |
Tumor location | 0.99 | ||
Upper | 120 (31.75%) | 131 (34.66%) | |
Middle | 53 (14.02%) | 53 (14.02%) | |
Low | 185 (48.94%) | 178 (47.09%) | |
Whole | 20 (5.29%) | 16 (4.23%) | |
Short diameter (μ ± sd, in cm) | 3.1 ± 2.4 | 3.1 ± 2.0 | 0.59 |
Long diameter (μ ± sd, in cm) | 4.5 ± 3.1 | 4.4 ± 2.8 | 0.72 |
Pathological type | 0.97 | ||
Adenocarcinoma | 299 (79.1%) | 298 (78.84%) | |
Signet ring cell carcinoma1 | 62 (16.4%) | 64 (16.93%) | |
Mucinous adenocarcinoma2 | 17 (4.5%) | 16 (4.23%) | |
Differentiation grade | 0.97 | ||
Well | 31 (8.2%) | 30 (7.94%) | |
Moderate | 175 (46.3%) | 174 (46.03%) | |
Poor | 172 (45.5%) | 174 (46.03%) | |
T stage | 0.98 | ||
T1 | 35 (9.26%) | 37 (9.79%) | |
T2 | 65 (17.2%) | 66 (17.46%) | |
T3 | 59 (15.61%) | 55 (14.55%) | |
T4 | 219 (57.94%) | 220 (58.2%) | |
N stage | 0.99 | ||
N0 | 135 (35.71%) | 139 (36.77%) | |
N1 | 78 (20.63%) | 78 (20.63%) | |
N2 | 63 (16.67%) | 58 (15.34%) | |
N3a | 60 (15.87%) | 61 (16.14%) | |
N3b | 42 (11.11%) | 42 (11.11%) | |
TNM stage | 0.48 | ||
IA | 25 (6.61%) | 33 (8.73%) | |
IB | 42 (11.11%) | 48 (12.70%) | |
IIA | 27 (7.14%) | 28 (7.41%) | |
IIB | 83 (21.96%) | 63 (16.67%) | |
IIIA | 63 (16.67%) | 55 (14.55%) | |
IIIB | 60 (15.87%) | 69 (18.25%) | |
IIIC | 78 (20.63%) | 82 (21.69%) | |
Vascular cancer embolus (yes) | 234 (61.9%) | 239 (63.23%) | 0.71 |
Hospital stay (μ ± sd, in days) | 14.2 ± 12.3 | 14.2 ± 11.8 | 0.39 |
Operative time (μ ± sd, in min) | 206.5 ± 58.5 | 208.8 ± 58.5 | 0.59 |
Blood loss (μ ± sd, in ml) | 153.6 ± 120.9 | 153.8 ± 153.4 | 0.22 |
Gastrectomy type | 0.76 | ||
Laparoscopic3 | 24 (6.35%) | 22 (5.82%) | |
Open | 354 (93.65%) | 356 (94.18%) | |
Resection range | 0.85 | ||
Total | 159 (42.06%) | 165 (43.65%) | |
Distal | 167 (44.18%) | 164 (43.39%) | |
Proximal | 48 (12.7%) | 43 (11.38%) | |
Thoraticabdominal joint | 4 (1.06%) | 6 (1.59%) | |
Multi-organ excision (yes) | 19 (5.03%) | 23 (6.08%) | 0.53 |
Reconstruction approach | 0.77 | ||
Billroth II | 76 (20.11%) | 85 (22.49%) | |
Billroth I | 86 (22.75%) | 73 (19.31%) | |
Roux-en-Y | 115 (30.42%) | 119 (31.48%) | |
Jejunal interposition | 52 (13.76%) | 55 (14.55%) | |
Other | 49 (12.96%) | 46 (12.17%) | |
ASA | 0.21 | ||
1 | 57 (15.08%) | 41 (10.85%) | |
2 | 254 (67.2%) | 270 (71.43%) | |
3 | 67 (17.72%) | 67 (17.72%) | |
N of lymph nodes dissected (μ ± sd) | 32.4 ± 11.3 | 31.7 ± 12.2 | 0.22 |
N of lymph nodes metastasis (μ ± sd) | 5.4 ± 8.5 | 5.2 ± 8.0 | 0.68 |